Related Experiment Video

Updated: Jun 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

It's all in for the HER family in tumorigenesis

Major Kenneth Lee1, Anupama Sharma, Brian J Czerniecki

  • 1Harrison Department of Surgical Research, Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA. leemk@uphs.upenn.edu

Expert Review of Vaccines
|December 22, 2009
PubMed

Insights

Mutations in ERBB4, a member of the EGF receptor family, drive melanoma growth by increasing cell proliferation and survival. Targeting ERBB4 offers a new therapeutic strategy for melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The Epidermal Growth Factor (EGF) receptor family, a group of receptor tyrosine kinases, plays a crucial role in various cancers.
  • While several family members are validated therapeutic targets, ERBB4's function in cancer and targeted therapies remain unclear.

Discussion:

  • This study reveals ERBB4 mutations in melanoma that enhance cell proliferation and survival, contributing to tumor development.
  • The findings indicate that ERBB4 mutations are oncogenic drivers in melanoma.
  • Targeting the EGF receptor family effectively reduces the proliferation of melanoma cells with these specific ERBB4 mutations.

Key Insights:

  • Identifies specific ERBB4 mutations driving melanoma proliferation and survival.
  • Demonstrates the efficacy of EGF receptor family inhibitors against ERBB4-mutated melanoma cells.
  • Establishes ERBB4 as a potential therapeutic target in melanoma.

Outlook:

  • Further research into ERBB4's role in tumorigenesis is warranted.
  • Development of targeted therapies specifically for ERBB4-mutated cancers is a promising avenue.
  • These findings could expand the utility of existing EGF receptor family inhibitors.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...